Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secondary cytoreduction vs chemotherapy in relapsed ovarian cancer after PARPi
NCT05607329Phase 3Recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- May 2021
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer (2 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-Free Survival. Started May 2021; status: recruiting.
02
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05607329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607329.